ArticleCancers2020

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.

Christoph Schliemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.